Recent clinical evidence has highlighted a potential link between popular diabetes drugs and vision-threatening conditions. Consequently, a new target trial emulation examined the ischemic optic neuropathy risk of glucagon-like peptide-1 receptor agonists (GLP-1RAs). This study compared these modern therapies against other common diabetes treatments to provide clear, actionable insights. Although the absolute risk remains low, clinicians must understand these findings to optimize patient care.
Evaluating the Ischemic Optic Neuropathy Risk
Specifically, researchers evaluated a large commercial claims database in the United States from 2017 to 2022. They analyzed diabetic patients aged 18 to 65 initiating GLP-1RAs, SGLT2 inhibitors, or DPP4 inhibitors. To minimize confounding, the investigators adjusted for more than 80 baseline covariates. Furthermore, they tracked the 18-month incidence of optic neuropathy as a proxy for nonarteritic anterior ischemic optic neuropathy (NAION). Ultimately, this rigorous design allowed them to emulate a randomized clinical trial and deliver highly reliable observational safety data.
Key Findings and Patient Risk Profiles
First, the investigators observed a small but statistically significant increase in the 18-month risk for ischemic optic neuropathy. Specifically, GLP-1RA users experienced 8.5 events per 10,000 patients compared to 5.5 events among SGLT2i users. Additionally, GLP-1RA users showed a higher risk than DPP4i users, who had 4.2 events per 10,000. These differences translate to a number needed to harm of 3,333 and 2,778, respectively. However, the absolute risk remains remarkably low for all groups.
Moreover, the risk was not uniform across all demographics. For instance, over 85% of optic neuropathy events in GLP-1RA users occurred in patients older than 50 years. Similarly, men accounted for over 70% of these cases. Consequently, older age, male sex, pre-existing cardiovascular disease, and existing ophthalmic conditions appeared to amplify the risk. In contrast, younger patients and women showed minimal differences in risk.
Study Limitations and Clinical Implications
First, clinicians must interpret these results cautiously because the study relies on observational data. Specifically, the database lacked diagnostic codes specifically for NAION, meaning the investigators used a proxy outcome. Furthermore, missing data on key clinical variables, such as body mass index and diabetes duration, could introduce residual confounding. Therefore, we cannot establish a definitive causal link based on these findings alone. Nevertheless, medical experts advise physicians to discuss these rare risks with high-risk patients before starting GLP-1RA therapy.
Frequently Asked Questions
Q1: What is ischemic optic neuropathy and how is it linked to GLP-1 receptor agonists?
Ischemic optic neuropathy involves sudden, severe restriction of blood flow to the optic nerve, which can cause permanent vision loss. Recently, observational studies have identified a small, statistically significant association between GLP-1 receptor agonists and this rare condition. However, these studies do not prove direct causation.
Q2: Who is at the highest risk for developing ischemic optic neuropathy while using GLP-1RAs?
The risk of developing this condition appears higher in specific patient groups. Specifically, the majority of cases occur in male patients and individuals aged 50 years or older. Additionally, patients with pre-existing cardiovascular disease or prior ophthalmic conditions may face an elevated risk. In contrast, women and younger patients experience minimal risk increase.
Q3: Should patients stop taking GLP-1 receptor agonists due to this concern?
No, patients should not discontinue their medication without consulting their physician. Although the study shows an association, the absolute risk of optic nerve injury remains extremely low. Furthermore, the substantial cardio-kidney and glycemic benefits of GLP-1 therapy usually far outweigh this rare hazard. Therefore, clinicians should individualize patient discussions based on personal risk factors.
References
- Reynolds KR et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation. Ann Intern Med. 2026 Jul 14. doi: 10.7326/ANNALS-25-00860. PMID: 42441967.
- Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(9):831-839. doi:10.1001/jamaophthalmol.2024.2296.
- European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines. 2025.